Is encorafenib plus binimetinib effective for BRAF V600E mutated Thyroid Cancer?
Encorafenib plus binimetinib is a targeted therapy combination that blocks the BRAF and MEK proteins, which are part of a signaling pathway that drives cancer growth in tumors with the BRAF V600E mutation. For patients with advanced or metastatic thyroid cancer that has this mutation, this combination has shown promising results. A phase 2 trial found that over half of patients responded to treatment, and it has been approved in Japan for this use 75. The therapy also appears to maintain quality of life and may be active against brain metastases 58.
What the research says
A Japanese phase 2 trial enrolled 22 patients with BRAF V600E-mutated thyroid cancer that was locally advanced or metastatic and not curable by surgery. The trial included 17 patients with differentiated thyroid cancer (DTC) and 5 with anaplastic thyroid cancer (ATC). The objective response rate (ORR), meaning the percentage of patients whose tumors shrank significantly, was 54.5% overall. For DTC, the ORR was 47.1%, and for ATC, it was 80.0% 7. The median progression-free survival (time without cancer growth) was 11.1 months for DTC and 4.8 months for ATC 7. These results led to approval of the combination in Japan 5.
Health-related quality of life was also assessed in the same trial. Patients completed questionnaires about their symptoms and well-being. Up to 20 weeks, most measures remained stable, with no significant worsening. Some areas even improved, such as social support and appetite loss, though joint pain tended to worsen 5. This suggests that the treatment does not severely harm daily living for most patients.
A case report described a patient with BRAF V600E-mutated anaplastic thyroid cancer who developed a brain metastasis while on treatment. After resuming encorafenib plus binimetinib, the brain lesion shrank within two weeks, and the patient also received stereotactic radiosurgery without major side effects 8. This indicates the combination may be effective against brain metastases, though more research is needed.
Another study looked at dabrafenib plus trametinib, a similar BRAF/MEK inhibitor combination, in 16 patients with BRAF V600E-positive thyroid cancer. It found that 2 patients with ATC who stopped that therapy later responded to encorafenib plus binimetinib, suggesting that switching between these combinations can be beneficial 9. This supports the idea that encorafenib plus binimetinib is a valuable option in this class of drugs.
What to ask your doctor
- Does my thyroid cancer have the BRAF V600E mutation, and would I be a candidate for encorafenib plus binimetinib?
- What are the expected benefits and side effects of this combination compared to other treatments like lenvatinib or dabrafenib plus trametinib?
- If I have brain metastases, could encorafenib plus binimetinib be an option for me?
- How will my response to treatment be monitored, and what are the signs that the therapy is working or not working?
- Are there any ongoing clinical trials for BRAF/MEK inhibitors in thyroid cancer that I might be eligible for?
This question is drawn from common patient questions about Oncology and answered using cited medical research. We do not provide individualized advice.